Sign inJoin waitlistJoin the waitlist

YJ

Yelena Janjigian

Chief, Gastrointestinal Oncology Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Gastrointestinal Oncology Service Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2006–2009
Internal Medicine
NYU Grossman School of Medicine
2003–2006
New York University Grossman School of Medicine
1999–2003

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised,…
The Lancet · 2021 · First of 29 authors · 2,551 citations

GK
Geoffrey Ku
50 papers
LT
Laura Tang
50 papers
DI
David Ilson
43 papers
VS
Vivian Strong
41 papers
SM
Steven Maron
37 papers
DM
Daniela Molena
35 papers
DC
Daniel Coit
31 papers
DJ
David Jones
28 papers
DK
David Kelsen
25 papers
David Solit
25 papers
AW
Abraham Wu
23 papers
SS
Smita Sihag
21 papers · 9 as a resident

Grants

Improving Radiolabeled Imaging and Targeting of HER2 Positive EG Cancers Using Lovastatin
National Cancer Institute · R01
PI · $3.4M · Sloan-Kettering Inst Can Research
2020–2026

Clinical trials

A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2029
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2027
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2027
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2027